Home/ News & Events
Exciting news! The ESID Juniors Call for presenters is open and we are accepting applications!
We are happy to inform you that the ESID Juniors Call for presenters for the next season of ESID Juniors Journal club and Clinical cases sessions is now OPEN!
Please, visit this page to find out more and to apply.
The New ESID Juniors Clinical Case Session is scheduled for next week!
We are happy to inform you that the New ESID Juniors Clinical Case session is scheduled for May 24, 2023!
Please, visit this page to find out more about the session and to register.
New ESID Grand Rounds Webinar is coming on May 30, 2023!
We are pleased to inform you that the ESID Clinical WP is organising a new Grand Rounds Webinar on May 30, 2023!
Please, visit this page to find out more about the webinar and to register.
KID interferon project
We are pleased to share information about the "KID_interferon" project, provided by Lorenzo Lodi.
Brief rationale of the project:
Monogenic type I interferonopathies (T1I) (like COPA syndrome (COPA), STING-associated vasculopathy with onset in infancy (SAVI) or some monogenic lupus) may display renal involvement. These entities are characterized by a systemic upregulation of type I interferons (IFN-I) which is central to the disease pathogenesis. However, a clear documentation of IFN-I upregulation at tissue level is still lacking. Indeed, this would be crucial to understand the selective organ involvement encountered in these diseases. The demonstration of tissue IFN-I upregulation can be performed applying human myxovirus resistance protein 1 (MxA) immunostaining to renal biopsies. While this characterization has been assessed in a few patients with T1I-related kidney diseases, it has never been performed in SAVI, COPA and several others T1I.
Here you can find more details about the project.
The ESID Biennial Meeting in 2026 will be held in Maastricht, The Netherlands!
We are excited to announce that the 22nd Biennial Meeting of ESID will be held in 2026 in Maastricht, The Netherlands!
In memoriam of Oksana Leontieva
It is with great sadness that we learned of the tragic and death of our colleague, Oksana Leontieva, a pediatric hematologist from Ukraine and a victim of a recent missile strike in Kyiv ( https://www.telegraph.co.uk/world-news/2022/10/11/ukraine-russia-war-oksana-leontyeva-killed-air-strikes-kyiv/).
We at ESID offer our deepest condolences to her family, friends and colleagues of the National Pediatric Ohmatdyt Hospital.
We take this somber moment to send our thoughts and prayers in the memory of all other fellow humans who needlessly perished as a result of the current war.
Call for observations - COPA syndrome
COPA syndrome is a recently defined type I interferonopathy caused by heterozygous mutations in the gene COPA, encoding coatomer protein subunit alpha that is involved in intra-cellular transport of cargo proteins1. Although the pathogenesis is not fully understood, mutations in COPA were shown to cause an accumulation of STING at the Golgi2 where it is activated and leads to constitutive type I interferon signalling i.e. the core feature of type I interferonopathies.
Call for participation: Malignancies in IEI – an ESID registry study
ESID registry Working Party is inviting the ESID registry participants to take part in the "Malignancies in IEI" study latest by August 31st 2022.
"Call for participation" IDDA2.1 score - an ESID registry prospective study
The IDDA score has already been available as optional module (tab) in the level 1 for your own use at the initial and follow up patient entries and is designed for all IEI with immune dysregulation. Now, I am inviting your active contribution to a prospective study until end of 2023 (prolongation possible), aiming to implement a powerful tool for assessment and monitoring of disease activity and phenotype patterns!
ESID COVID-19 Statement, March 2022
Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges.